Purity:SDS-PAGE

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC

The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) is 100%, determined by SEC-HPLC.

Bioactivity:ELISA

Immobilized human PD-L1 His at 2 ug/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab), EC50=0.005894 ug/mL.

Bioactivity:FACS

Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=1.533 nM.

Function:Internalization

The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.

Research in vivo

Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.

-25~-15℃保存，有效期1年。